Alto Neuroscience News

Buy Rating for Alto Neuroscience: Promising Trials in MDD and Advances in CIAS Treatment

TipRanksMay 16 04:17 ET

TD Cowen Remains a Buy on Alto Neuroscience, Inc. (ANRO)

TipRanksMay 15 12:16 ET

Alto Neuroscience Analyst Ratings

BenzingaMar 25 11:27 ET

Stifel Nicolaus Reaffirms Their Buy Rating on Alto Neuroscience, Inc. (ANRO)

TipRanksMar 25 07:45 ET

Buy Rating Affirmed for Alto Neuroscience on Strong Pipeline and Solid Financials

TipRanksMar 25 06:45 ET

Buy Rating Affirmed: Alto Neuroscience's Promising Clinical Trials Signal Market Potential

TipRanksMar 24 21:47 ET

Alto Neuroscience's Innovative Therapies for MDD Show Promise in Phase 2b Trials: A Buy Rating by Ritu Baral

TipRanksFeb 27 05:54 ET

Alto Neuroscience Analyst Ratings

BenzingaFeb 27 05:50 ET

Analysts Offer Insights on NA Companies: Fractyl Health, Inc. (GUTS) and Alto Neuroscience, Inc. (ANRO)

TipRanksFeb 27 04:40 ET

Buy Rating Affirmed for Alto Neuroscience on Innovative Precision Psychiatry and Promising Drug Candidates

TipRanksFeb 27 04:36 ET

Alto Neuroscience Stock Upgraded as Jefferies Sees BIG Potential

InvestingFeb 27 03:56 ET